
Core Insights - Cumberland Pharmaceuticals Inc. reported a strong financial performance with combined net revenues of $10.8 million in Q2 2025, marking a 10% increase year-over-year [1][12] - Year-to-date revenues reached $22.6 million, reflecting a 23% increase compared to the first half of 2024 [1][12] - The company ended the quarter with total assets of approximately $68 million and shareholders' equity of $28 million [2][14] Financial Performance - Q2 2025 net revenues included $2.8 million from Kristalose®, $3.1 million from Sancuso®, $2.7 million from Vibativ®, and $1.6 million from Caldolor® [12] - Total operating expenses for Q2 2025 were $11.6 million, leading to a net loss of approximately $741,000 for the quarter [13][33] - Year-to-date net income was approximately $516,000, with adjusted earnings of $2.8 million or $0.18 per diluted share [13][37] Product Developments - Cumberland announced the availability of the Vibativ 4-Vial Starter Pak through a new supply arrangement with Vizient Inc., enhancing access for healthcare providers [3][4] - A new pharmacokinetic analysis of Vibativ supports optimized dosing strategies for treating life-threatening gram-positive infections [5] - Breakthrough findings from the Phase II FIGHT DMD trial for ifetroban showed a 5.4% improvement in cardiac function in patients with Duchenne muscular dystrophy [6][7] Clinical Trials - Cumberland is conducting a Phase II clinical program for ifetroban in patients with Systemic Sclerosis, with enrollment completed [8] - The FIGHTING FIBROSIS™ trial is underway for patients with Idiopathic Pulmonary Fibrosis, with patient enrollment ongoing [9] - A study on Caldolor® demonstrated its safety and efficacy for managing post-operative pain in patients aged 60 and older [10][11] Balance Sheet - As of June 30, 2025, Cumberland had total assets of approximately $68 million, with $16 million in cash and cash equivalents [14][31] - Total liabilities were reported at $40 million, including $5 million on the company's credit facility [14][31] - Shareholders' equity stood at $28 million, reflecting a solid financial position [14][32]